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SUMMARY
Studies from the Western hemisphere have established
the efficacy and safety of tegaserod in women with
irritable bowel syndrome and constipation. This review
summarizes the results of recent studies from around
the world that confirm the efficacy and safety of
tegaserod, and expand our understanding of the role
of this drug in the treatment of patients with irritable
bowel syndrome.
INTRODUCTION
An ideal treatment for patients with irritable bowel
syndrome and constipation should target the under-
lying pathophysiology of the disorder and, in so
doing, offer efficacy for the multiple symptoms of
irritable bowel syndrome. Such a medication ideally
should offer a rapid onset of action, sustained
effectiveness, be devoid of significant adverse effects
and reduce the socio-economic impact of irritable
bowel syndrome.
Unfortunately, most of the traditional therapies for
irritable bowel syndrome and constipation (anti-
spasmodics, fibre, tricyclic antidepressants, etc.) do
not fulfil these idealized attributes. With few excep-
tions, these traditional therapies for irritable bowel
syndrome and constipation have not been proven to
be effective in rigorously designed randomized con-
trolled trials. When therapies have shown benefit for
irritable bowel syndrome, they have typically
improved only individual symptoms (i.e. fibre for
constipation) as opposed to the global consortium of
symptoms that constitutes irritable bowel syndrome
and constipation.1
TEGASEROD FOR IRRITABLE BOWEL SYNDROME
AND CONSTIPATION
More recently, serotonin has been found to play an
important role in gastrointestinal motor function,
secretion and sensation.2 To date, seven different
serotonin receptor subclasses have been identified. The
5-HT3 and 5-HT4 receptor subclasses have been best
characterized in the gastrointestinal tract. There is high-
quality evidence from well-designed randomized con-
trolled trials that 5-HT3 antagonists and 5-HT4 agonists
are effective for the treatment of specific subsets of
irritable bowel syndrome patients.3 Tegaserod is a
highly selective, partial 5-HT4 receptor agonist.
Through its effects at the 5-HT4 receptor, tegaserod
has a number of physiological effects. It stimulates the
peristaltic reflex, resulting in the acceleration of intes-
tinal and colonic transit. It also stimulates chloride
secretion within the intestinal tract. Studies in animals
and preliminary work in humans also suggest that
tegaserod has effects on visceral sensation.4 Whether
these effects on visceral sensation are a primary effect
on afferent pathways or a secondary effect related to
influences on motility and secretory function of the gut
remains to be elucidated. The combined physiological
effects of tegaserod make it an attractive candidate for
the treatment of patients with irritable bowel syndrome
and constipation.
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PIVOTAL TRIALS OF TEGASEROD FOR IRRITABLE
BOWEL SYNDROME AND CONSTIPATION
Three large, randomized, parallel group, double-blind
trials have evaluated the effectiveness of tegaserod
(2 mg or 6 mg b.d.) vs. placebo in patients with
irritable bowel syndrome and constipation from the
Western hemisphere.5–7 The treatment phase of each
trial lasted 12 weeks. Nearly 3000 patients were
included in these clinical trials. Unlike most previous
studies addressing the effectiveness of traditional
medical therapies in irritable bowel syndrome, the
tegaserod trials conformed to the rigorous clinical
study design recommendations of the ROME commit-
tee, a group of international experts on functional
gastrointestinal disorders.8
The primary end-point for the three pivotal trials was
the treated subjects’ global assessment of the relief of
irritable bowel syndrome symptoms. To determine the
effect of tegaserod or placebo on the subjects’ global
assessment, patients were asked to consider how they
had felt in the past week with regard to their irritable
bowel syndrome, in particular with regard to overall
well-being, altered bowel habits and symptoms of
abdominal discomfort and pain. In this way, the
subjects’ global assessment took into consideration the
entire constellation of symptoms important in irritable
bowel syndrome. Efficacy was based on the subjects’
global assessment response obtained in the final
4 weeks of the treatment phase. A series of graded
responses was used to assess the effect of tegaserod or
placebo on global irritable bowel syndrome symptoms.
In addition to the primary outcome measure, a number
of specific individual symptoms important in irritable
bowel syndrome, including abdominal pain and dis-
comfort, change in bowel habits, satisfaction with bowel
habits and relief of bloating, served as secondary
outcomes in these three randomized trials.
In these studies, the median age of the study popula-
tion was 43.7 years, with 90% being female and 87%
Caucasian. The median duration of irritable bowel
syndrome symptoms was 14.4 years. The efficacy of
tegaserod vs. placebo on the primary outcome measure
of the subjects’ global assessment is summarized in
Table 1. Each of the trials found that tegaserod led to a
statistically significant improvement in the subjects’
global assessment compared with placebo. This
improvement in the subjects’ global assessment was
typically seen within a week of initiation of drug
therapy. In addition, tegaserod led to a significant and
sustained improvement in the subjects’ global assess-
ment, compared with placebo, over the duration of the
12-week treatment phase of each study. The sustained
nature of the improvement in the subjects’ global
assessment suggests that tolerance, or tachyphylaxis,
to the drug does not develop. Two of the studies
included a 4-week observation period following treat-
ment discontinuation.6, 7 The improvement in the
subjects’ global assessment observed during treatment
decreased after drug discontinuation to similar degrees
in patients randomized to tegaserod or placebo. Thus,
there was no evidence of rebound in irritable bowel
syndrome symptoms following the withdrawal of tegas-
erod.
These clinical trials also found tegaserod to be well
tolerated. The safety profile of tegaserod has recently
been confirmed in a 12-month safety trial.9 The most
common side-effects reported in this trial included
diarrhoea (10%), headache (8%), abdominal pain (7%)
and flatulence (6%). As a consequence of these pivotal
trials, tegaserod is currently approved by the US Food
and Drug Administration for the treatment of women
with irritable bowel syndrome and constipation.
TEGASEROD: RECENT INTERNATIONAL STUDIES
A number of recent international studies have offered
new insights into the role of tegaserod for patients with
irritable bowel syndrome. Documentation of efficacy in
non-Caucasian populations can be found in a random-
ized, controlled, 4-week treatment trial from China in
over 500 patients (mean age, 39 years; 82% females)
with irritable bowel syndrome and constipation. This
trial found that tegaserod, 6 mg b.d., was significantly
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more effective than placebo in improving the subjects’
global assessment of overall irritable bowel syndrome
symptoms.10 Furthermore, tegaserod was more effective
than placebo in improving individual symptoms, inclu-
ding abdominal pain, bloating and constipation. Over-
all, tegaserod was well tolerated, with the three most
commonly reported side-effects being diarrhoea, abdom-
inal pain and dizziness (each reported in less than 3% of
those randomized to tegaserod).
Further clinical information from Asia and the Pacific
Rim can be gleaned from the Zelmac Asia-Pacific (ZAP)
study. This large randomized controlled trial found
tegaserod, 6 mg b.d., to be significantly more effective
than placebo for both global and individual symptoms
in patients with non-diarrhoea irritable bowel syn-
drome.11 In addition to confirming the effectiveness of
tegaserod in an Asian population, the ZAP trial also
found that tegaserod may offer an option in patients
who do not fulfil the criteria for irritable bowel
syndrome and constipation alone or irritable bowel
syndrome and diarrhoea alone, i.e. alternators. Unfor-
tunately, as a result of the study design, it was not
possible to perform a subgroup analysis to address the
efficacy of tegaserod in only those with irritable bowel
syndrome and alternating constipation and diarrhoea.
Further evidence that irritable bowel syndrome
patients, other than those with irritable bowel syn-
drome and constipation, may respond to tegaserod
comes from a 12-week, randomized controlled trial
including more than 600 patients (mean age, 44 years;
86% females) with non-diarrhoea irritable bowel syn-
drome from northern Europe [Tegaserod Nordic trial
(TENOR)]. This trial found that a greater percentage of
those treated with tegaserod 6 mg b.d. than with
placebo experienced overall satisfactory relief of their
irritable bowel syndrome symptoms using a binary
outcome measure.12 Like the ZAP study, the TENOR
study suggested that tegaserod benefitted irritable bowel
syndrome patients who did not have diarrhoea as their
primary bowel complaint. Another interesting finding
from this study was that patients with a disease
duration of less than 10 years were more likely to
respond to tegaserod than those with irritable bowel
syndrome for more than 10 years. The therapeutic gain
for the primary end-point over placebo for those
randomized to tegaserod with a disease duration of less
than 10 years was 10–26%, compared with 5–15% for
the total study population, over the 12-week treatment
period. In this study, diarrhoea was the most commonly
reported adverse event with tegaserod (tegaserod 9.2%
vs. placebo 1.3%).
A recent open-label study from Latin America
(LATAM) evaluated the natural history of irritable
bowel syndrome after the withdrawal of tegaserod
therapy.13 All patients with irritable bowel syndrome
and constipation (mean age, 49 years; 92% females;
48% Hispanics) received 4 weeks of open-label therapy
with tegaserod 6 mg b.d. Eighty-two per cent (553/
678) of patients experienced overall symptom relief with
tegaserod using a binary satisfactory relief outcome
measure. Following the open-label treatment period,
544 patients with irritable bowel syndrome and consti-
pation were randomized to receive continued tegaserod
or withdrawal from tegaserod. Although only 10% of
patients who remained on tegaserod suffered a recur-
rence of their irritable bowel syndrome and constipation
symptoms, 67% of those who were withdrawn from
tegaserod therapy experienced a symptomatic recur-
rence by the end of the 8-week withdrawal period
(Figure 1). The mean time to symptom recurrence after
























   
   















Figure 1. Effect of tegaserod withdrawal or continuation in
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Figure 2. Re-treatment was as effective as initial treatment with
tegaserod for irritable bowel syndrome and constipation (IBS-C).15
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were reported in a study of comparable design recently
conducted in the UK.14
In a study from Germany, including over 500 patients
with irritable bowel syndrome and constipation (mean
age, 52 years; 72% females), patients were initially
treated with tegaserod, 6 mg b.d., for 12 weeks.15
During this initial treatment phase, 85% (436/513) of
patients with irritable bowel syndrome and constipation
responded to therapy with tegaserod using a binary
satisfactory relief outcome measure. This was followed
by a 4–8-week withdrawal phase. As in the LATAM and
UK studies, the majority of patients suffered a recur-
rence of their irritable bowel syndrome symptoms
following the withdrawal of tegaserod. The withdrawal
phase of the study was then followed by a 4-week
re-treatment period. Of the patients with irritable bowel
syndrome and constipation who participated in the
re-treatment phase of the study, 89% (274/307)
responded to a second course of tegaserod (Figure 2).
An open-label study from Pakistan provides some
insight into the potential utility of tegaserod in males
with irritable bowel syndrome and constipation.16
This study, which included 117 patients (mean age,
37.5 years; 81 males and 36 females), found that
participants from both genders experienced significant
improvements in abdominal pain/discomfort, straining
and urgency with tegaserod. Men also experienced a
significant improvement in weekly stool frequency
with tegaserod (Table 2). Clearly, more information
from high-quality studies is needed in order to
determine the utility of tegaserod in males with
irritable bowel syndrome, but these preliminary data
are promising.
CONCLUSIONS
Studies from around the world continue to demonstrate
the efficacy and safety of tegaserod in ethnically diverse
populations of patients with irritable bowel syndrome
and constipation. The data discussed above have helped
to shed light on a number of clinical management issues
involving the use of tegaserod in irritable bowel
syndrome patients. Although preliminary studies are
encouraging, confirmation of the efficacy in men with
irritable bowel syndrome and constipation and in
irritable bowel syndrome patients with alternating
diarrhoea and constipation is necessary before recom-
mending the routine use of tegaserod in these special
populations. Furthermore, important questions remain
with regard to the efficacy of tegaserod when given for
longer than 12 weeks, and whether treatment with this
drug reduces overall health care utilization and costs.
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